EGI
OCUL icon

EAM Global Investors’s Ocular Therapeutix OCUL Stock Holding History

EAM Global Investors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-163,584
Closed -$3.39M – 172
2020
Q4 		$3.39M Sell
163,584
-41,383
-20% -$615K 0.92% 28
2020
Q3 		$1.56M Sell
204,967
-60,349
-23% -$501K 0.57% 87
2020
Q2 		$2.21M Hold
265,316
– – 0.99% 33
2020
Q1 		$1.31M Buy
+265,316
New +$1.31M 0.77% 65

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Global Investors's OCUL Position: Q1 2021 in Review

EAM Global Investors sold out of Ocular Therapeutix (OCUL) in Q1 2021, closing a stake of 163,584 shares — an estimated $3.39M sold.

EAM Global Investors first reported a position in OCUL in Q1 2020 and held it in 4 quarters. The position peaked at $3.39M in Q4 2020. 154 funds tracked by Wall St. Rank hold OCUL as of Q1 2021.

  • EAM Global Investors reported no remaining Ocular Therapeutix position as of Q1 2021 after selling out during the quarter.
  • EAM Global Investors sold 163,584 Ocular Therapeutix shares in Q1 2021, an estimated $3.39M.
  • EAM Global Investors first reported a position in Ocular Therapeutix in Q1 2020 and held it in 4 quarters.
  • EAM Global Investors's Ocular Therapeutix position peaked at $3.39M in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2021.

Based on EAM Global Investors's 13F filing for Q1 2021, filed 11 May 2021.